OUR Portfolio
Tullis-Dickerson Capital Focus II, L.P.

			Adams Respiratory Therapeutics, Inc. Adams is a specialty pharmaceutical company focused on late stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders. Adams was acquired by Reckitt Benckiser in January 2008.

			Biolex Therapeutics, Inc. Biolex is a clinical-stage biopharmaceutical company that uses its patented LEX System(SM) to develop hard-to-make therapeutic proteins and to optimize monoclonal antibodies. The LEX System is a novel technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. The company's product candidates are designed to provide superior efficacy/tolerability profiles and to address large, proven pharmaceutical markets.

			Genoptix, Inc. (NasdaqGM: GXDX) Genoptix provides the full range of personalized medicine services to hematologists and oncologists to enable more informed management of cancer patients from diagnosis through treatment and follow-up.

			LivHOME, Inc. LivHOME is the nation's largest provider of professionally led at-home care for seniors. The company is dedicated to finding solutions that enable older adults to remain in their homes as long as possible.

			SupplyPro, Inc. SupplyPro designs, develops and sells proprietary, web-enabled point-of-use dispensing applications and solutions that provide secured management of inventory and related assets, automatic transaction tracking, and electronic reordering for industrial and office environments.

			Synageva BioPharma Corp. Synageva BioPharma Corporation is a biopharmaceutical company dedicated to developing and commercializing novel, next-generation, and follow-on protein therapeutics that leverage the unique competitive advantages of its proprietary Synageva Expression Platform. Synageva's development programs address specific unmet medical or market needs in several therapeutic areas including oncology, organ dysfunction, autoimmune diseases and rare disorders.

			TransMolecular, Inc. TMI is a biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat human cancers having inadequate pharmaceutical alternatives. The company has built a strong technology platform around targeted therapeutics that bind only to specific cancer cell types.

			ViaCell, Inc. ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. In addition, ViaCell's reproductive health business unit commercializes ViaCord®, a product that offers expectant families the option of preserving their babies' stem cells from umbilical cord blood. ViaCell was acquired by PerkinElmer in November 2007.